Qing Peng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Qing Peng has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Liyuan Hao
Department of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of China
3 shared publications- Liyuan Hao
Department of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, P. R. China
3 shared publications Shenghao Li
Department of Integrated Traditional Chinese and Western Medicine Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, People’s Republic of China
3 shared publicationsYinglin Guo
Department of Pathobiology and Immunology Hebei University of Chinese Medicine Shijiazhuang China
3 shared publicationsCaige Li
Department of Pathobiology and Immunology Hebei University of Chinese Medicine Shijiazhuang China
2 shared publications- Fei Yu
Department of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of China
2 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-38
Nanotherapeutic Strategies for MASLD: From Pathological Mechanisms to Targeted Delivery Systems
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a progressive metabolic liver disorder driven by hepatic lipid overload, oxidative stress, mitochondrial dysfunction, innate immune activation, insulin resistance, gut–liver axis dysregulation, and liver fibrosis. These interconnected pathological processes involve hepatocyte injury, macrophage-mediated inflammation, liver sinusoidal endothelial cell dysfunction, hepatic stellate cell activation, and extracellular matrix deposition. However, conventional therapeutic agents are often limited by poor solubility, insufficient stability, low intrahepatic exposure, nonspecific distribution, and inadequate target-cell selectivity. Nanoparticle-based delivery systems may overcome these limitations by improving drug stability, hepatic accumulation, controlled release, and cell-specific delivery. This review summarizes recent advances in nanotherapeutic strategies for MASLD from three complementary perspectives: intervention in key pathological processes, cell-specific delivery to major hepatic cell populations, and the design characteristics of different nanoplatforms. We discuss nanodelivery strategies targeting lipid metabolic dysfunction, oxidative injury, inflammation, insulin resistance, gut–liver axis dysfunction, and fibrogenesis, as well as delivery approaches directed at hepatocytes, hepatic stellate cells, liver macrophages, and liver sinusoidal endothelial cells. Multicellular co-delivery strategies for modulating pathological crosstalk are also considered. In addition, we compare the advantages and limitations of inorganic nanoparticles, polymeric nanoparticles, liposomes and other lipid-based nanosystems, and bio-derived or biomimetic nanocarriers. Particular attention is given to how carrier composition, physicochemical properties, surface functionalization, and release behavior can be matched with therapeutic cargoes, target cells, and pathological processes. Although these platforms provide opportunities for multi-process and cell-specific intervention in MASLD, most evidence remains preclinical. Major barriers to clinical translation include long-term safety, controllable biodistribution, differences between experimental models and human disease, scalable manufacturing, batch-to-batch consistency, and standardized quality evaluation. Addressing these issues during nanoplatform design and assessment will be essential for translating targeted nanodelivery systems into clinically applicable therapies for MASLD.
- 1 September 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-38
Open AccessNanotherapeutic Strategies for MASLD: From Pathological Mechanisms to Targeted Delivery Systems
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a progressive metabolic liver disorder driven by hepatic lipid overload, oxidative stress, mitochondrial dysfunction, innate immune activation, insulin resistance, gut–liver axis dysregulation, and liver fibrosis. These interconnected pathological processes involve hepatocyte injury, macrophage-mediated inflammation, liver sinusoidal endothelial cell dysfunction, hepatic stellate cell activation, and extracellular matrix deposition. However, conventional therapeutic agents are often limited by poor solubility, insufficient stability, low intrahepatic exposure, nonspecific distribution, and inadequate target-cell selectivity. Nanoparticle-based delivery systems may overcome these limitations by improving drug stability, hepatic accumulation, controlled release, and cell-specific delivery. This review summarizes recent advances in nanotherapeutic strategies for MASLD from three complementary perspectives: intervention in key pathological processes, cell-specific delivery to major hepatic cell populations, and the design characteristics of different nanoplatforms. We discuss nanodelivery strategies targeting lipid metabolic dysfunction, oxidative injury, inflammation, insulin resistance, gut–liver axis dysfunction, and fibrogenesis, as well as delivery approaches directed at hepatocytes, hepatic stellate cells, liver macrophages, and liver sinusoidal endothelial cells. Multicellular co-delivery strategies for modulating pathological crosstalk are also considered. In addition, we compare the advantages and limitations of inorganic nanoparticles, polymeric nanoparticles, liposomes and other lipid-based nanosystems, and bio-derived or biomimetic nanocarriers. Particular attention is given to how carrier composition, physicochemical properties, surface functionalization, and release behavior can be matched with therapeutic cargoes, target cells, and pathological processes. Although these platforms provide opportunities for multi-process and cell-specific intervention in MASLD, most evidence remains preclinical. Major barriers to clinical translation include long-term safety, controllable biodistribution, differences between experimental models and human disease, scalable manufacturing, batch-to-batch consistency, and standardized quality evaluation. Addressing these issues during nanoplatform design and assessment will be essential for translating targeted nanodelivery systems into clinically applicable therapies for MASLD.
- 16 June 2026
- Published by World Scientific Pub Co Pte Ltd in The American Journal of Chinese Medicine
- p. 1-25
Ginsenosides in Liver Fibrosis: Pharmacological Actions and Therapeutic Potential
Liver fibrosis (LF) represents a critical pathological stage in the progression of various chronic liver diseases, and is characterized by the sustained activation of hepatic stellate cells (HSCs) and excessive deposition of extracellular matrix (ECM). These processes ultimately lead to cirrhosis and even hepatocellular carcinoma. Current therapeutic strategies for LF primarily rely on etiological interventions and supportive management. However, due to the complex pathogenesis of LF, involving multiple interconnected signaling pathways, effective and specific antifibrotic therapies remain lacking. Therefore, the development of multi-target and system-level therapeutic strategies for the treatment of LF is of considerable importance. Ginsenosides, the major bioactive components of Panax ginseng, exhibit multi-component and multi-target pharmacological properties and have shown broad potential in the prevention and treatment of liver fibrosis. Accumulating evidence indicates that several ginsenosides, including Rg1, Rb1, Rg3, Rh1, Rd, and the metabolite Compound K, exert significant antifibrotic effects across various experimental models. This review systematically summarizes the pharmacological mechanisms of ginsenosides in liver fibrosis and integrates their effects from a mechanistic perspective. Overall, ginsenosides directly target key fibrogenic processes by inhibiting HSCs activation and proliferation, promoting apoptosis, reducing ECM synthesis, and facilitating ECM degradation. In addition, they indirectly modulate fibrosis progression by regulating upstream amplifying factors such as inflammation, oxidative stress, and the immune microenvironment. Furthermore, ginsenosides also influence cell fate-related processes, including autophagy and ferroptosis, in a cell-type-dependent manner. In hepatocytes, maintaining appropriate autophagic activity and suppressing lipid peroxidation generally confers protective effects. In HSCs, by contrast, the inhibition of protective autophagy or induction of ferroptosis appears to be more relevant to antifibrotic efficacy. Although substantial experimental evidence supports the antifibrotic potential of ginsenosides, their clinical translation remains limited by low bioavailability, unclear active forms in vivo, and the lack of high-quality clinical studies. Future investigations should focus on identifying key molecular targets and underlying mechanisms through multi-omics approaches and structure–activity relationship analyses. Well-designed clinical trials should likewise be conducted to evaluate the safety and therapeutic efficacy of ginsenosides and, thereby, facilitate their clinical application in liver fibrosis.
- 16 June 2026
- Published by World Scientific Pub Co Pte Ltd in The American Journal of Chinese Medicine
- p. 1-25
Ginsenosides in Liver Fibrosis: Pharmacological Actions and Therapeutic Potential
Liver fibrosis (LF) represents a critical pathological stage in the progression of various chronic liver diseases, and is characterized by the sustained activation of hepatic stellate cells (HSCs) and excessive deposition of extracellular matrix (ECM). These processes ultimately lead to cirrhosis and even hepatocellular carcinoma. Current therapeutic strategies for LF primarily rely on etiological interventions and supportive management. However, due to the complex pathogenesis of LF, involving multiple interconnected signaling pathways, effective and specific antifibrotic therapies remain lacking. Therefore, the development of multi-target and system-level therapeutic strategies for the treatment of LF is of considerable importance. Ginsenosides, the major bioactive components of Panax ginseng, exhibit multi-component and multi-target pharmacological properties and have shown broad potential in the prevention and treatment of liver fibrosis. Accumulating evidence indicates that several ginsenosides, including Rg1, Rb1, Rg3, Rh1, Rd, and the metabolite Compound K, exert significant antifibrotic effects across various experimental models. This review systematically summarizes the pharmacological mechanisms of ginsenosides in liver fibrosis and integrates their effects from a mechanistic perspective. Overall, ginsenosides directly target key fibrogenic processes by inhibiting HSCs activation and proliferation, promoting apoptosis, reducing ECM synthesis, and facilitating ECM degradation. In addition, they indirectly modulate fibrosis progression by regulating upstream amplifying factors such as inflammation, oxidative stress, and the immune microenvironment. Furthermore, ginsenosides also influence cell fate-related processes, including autophagy and ferroptosis, in a cell-type-dependent manner. In hepatocytes, maintaining appropriate autophagic activity and suppressing lipid peroxidation generally confers protective effects. In HSCs, by contrast, the inhibition of protective autophagy or induction of ferroptosis appears to be more relevant to antifibrotic efficacy. Although substantial experimental evidence supports the antifibrotic potential of ginsenosides, their clinical translation remains limited by low bioavailability, unclear active forms in vivo, and the lack of high-quality clinical studies. Future investigations should focus on identifying key molecular targets and underlying mechanisms through multi-omics approaches and structure–activity relationship analyses. Well-designed clinical trials should likewise be conducted to evaluate the safety and therapeutic efficacy of ginsenosides and, thereby, facilitate their clinical application in liver fibrosis.
- Open Access
- 1 November 2024
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 9665-9681
Targeting Glycolytic Reprogramming in Cholangiocarcinoma: A Novel Approach for Metabolic Therapy
Cholangiocarcinoma (CCA) is a highly aggressive and poorly prognostic tumor. Due to the lack of early symptoms, diagnosing CCA remains challenging, often occurring at an advanced stage. Therefore, exploring the underlying mechanisms of CCA development and identifying potential biomarkers and therapeutic targets is crucial. Recently, metabolic reprogramming in cancer cells has emerged as a hallmark of the disease. Glycolysis has been identified as a central component of metabolic reprogramming in CCA, with multiple signaling pathways and key enzymes playing significant roles. Additionally, non-coding RNAs (ncRNAs) and post-translational modifications of proteins are also involved in regulating glycolysis in CCA. In this review, we provide a comprehensive summary of the alterations in cancer metabolism and the diverse signaling pathways involved, as they might exert an impact on the development of CCA. Overall, targeting glycolysis holds considerable promise as a crucial strategy for enhancing the therapeutic outcomes of CCA. In addition, we performed a bioinformatic analysis of the relationship between CCA and glycolysis to identify and investigate potential targets. The purpose of this study is to provide a theoretical basis for the development of CCA targets.
- 1 November 2024
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 9665-9681
Open AccessTargeting Glycolytic Reprogramming in Cholangiocarcinoma: A Novel Approach for Metabolic Therapy
Cholangiocarcinoma (CCA) is a highly aggressive and poorly prognostic tumor. Due to the lack of early symptoms, diagnosing CCA remains challenging, often occurring at an advanced stage. Therefore, exploring the underlying mechanisms of CCA development and identifying potential biomarkers and therapeutic targets is crucial. Recently, metabolic reprogramming in cancer cells has emerged as a hallmark of the disease. Glycolysis has been identified as a central component of metabolic reprogramming in CCA, with multiple signaling pathways and key enzymes playing significant roles. Additionally, non-coding RNAs (ncRNAs) and post-translational modifications of proteins are also involved in regulating glycolysis in CCA. In this review, we provide a comprehensive summary of the alterations in cancer metabolism and the diverse signaling pathways involved, as they might exert an impact on the development of CCA. Overall, targeting glycolysis holds considerable promise as a crucial strategy for enhancing the therapeutic outcomes of CCA. In addition, we performed a bioinformatic analysis of the relationship between CCA and glycolysis to identify and investigate potential targets. The purpose of this study is to provide a theoretical basis for the development of CCA targets.
- Open Access
- 7 October 2023
- Published by Atlantis Press SARL
- p. 696-705
Will Audit Background Executives Affect the Quality of Corporate Disclosure?
- 7 October 2023
- Published by Atlantis Press SARL
- p. 696-705
Open AccessWill Audit Background Executives Affect the Quality of Corporate Disclosure?
- 28 December 2022
- Published by Wiley in Phytotherapy Research
- Vol. 37 (5) , 1740-1753
Dihydroartemisinin broke the tumor immunosuppressive microenvironment by inhibiting YAP1 expression to enhance anti‐PD‐1 efficacy
The efficacy of anti‐PD‐1 therapy is not as expected in hepatocellular carcinoma (HCC). YAP1 was overexpressed and activated in HCC. The mechanism of YAP1 in HCC immune escape is unclear. Anti‐PD‐1 treatment increased YAP1 expression in liver tumor cells, and exhausted CD4+ and CD8+ T cells in the blood and spleen of liver tumor mice. YAP1 knockdown suppressed PD‐L1 expression, which was involved in JAK1/STAT1, 3 pathways. Moreover, Yap1 knockout elevated CD4+ and CD8+ T cells in liver tumor niche. Consistently, verteporfin, YAP1 inhibitor, decreased TGF‐β and IFN‐γ in liver tumor niche and exhausted CD8+ T cell in the spleen. DHA suppressed YAP1 expression and break immune evasion in liver tumor niche, characterized by decreased PD‐L1 in liver tumor cells and increased CD8+ T cell infiltration. Furthermore, DHA combined with anti‐PD‐1 treatment promoted CD4+ T cell infiltration in the spleen and CD8+ T cell in tumor tissues of mice. In summary, YAP1 knockdown in liver tumor cells suppressed PD‐L1 expression and recruited cytotoxic T lymphocytes (CTLs), leading to break immune evasion in tumor niche. Mechanistically, YAP1 knockdown suppressed PD‐L1 expression, which was involved in JAK1/STAT1, 3 pathways. Finally, DHA inhibited YAP1 expression, which not only inhibited liver tumor proliferation but also break the immunosuppressive niche in liver tumor tissues and improve the effect of anti‐PD‐1 therapy.
- 28 December 2022
- Published by Wiley in Phytotherapy Research
- Vol. 37 (5) , 1740-1753
Dihydroartemisinin broke the tumor immunosuppressive microenvironment by inhibiting YAP1 expression to enhance anti‐PD‐1 efficacy
The efficacy of anti‐PD‐1 therapy is not as expected in hepatocellular carcinoma (HCC). YAP1 was overexpressed and activated in HCC. The mechanism of YAP1 in HCC immune escape is unclear. Anti‐PD‐1 treatment increased YAP1 expression in liver tumor cells, and exhausted CD4+ and CD8+ T cells in the blood and spleen of liver tumor mice. YAP1 knockdown suppressed PD‐L1 expression, which was involved in JAK1/STAT1, 3 pathways. Moreover, Yap1 knockout elevated CD4+ and CD8+ T cells in liver tumor niche. Consistently, verteporfin, YAP1 inhibitor, decreased TGF‐β and IFN‐γ in liver tumor niche and exhausted CD8+ T cell in the spleen. DHA suppressed YAP1 expression and break immune evasion in liver tumor niche, characterized by decreased PD‐L1 in liver tumor cells and increased CD8+ T cell infiltration. Furthermore, DHA combined with anti‐PD‐1 treatment promoted CD4+ T cell infiltration in the spleen and CD8+ T cell in tumor tissues of mice. In summary, YAP1 knockdown in liver tumor cells suppressed PD‐L1 expression and recruited cytotoxic T lymphocytes (CTLs), leading to break immune evasion in tumor niche. Mechanistically, YAP1 knockdown suppressed PD‐L1 expression, which was involved in JAK1/STAT1, 3 pathways. Finally, DHA inhibited YAP1 expression, which not only inhibited liver tumor proliferation but also break the immunosuppressive niche in liver tumor tissues and improve the effect of anti‐PD‐1 therapy.
- 6 September 2022
- Published by Springer Nature in Journal of Natural Medicines
- Vol. 77 (1) , 28-40
Dihydroartemisinin inhibited the Warburg effect through YAP1/SLC2A1 pathway in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) was the third most common cause of cancer death. But it has only limited therapeutic options, aggressive nature, and very low overall survival. Dihydroartemisinin (DHA), an anti-malarial drug approved by the Food and Drug Administration (FDA), inhibited cell growth in HCC. The Warburg effect was one of the ten new hallmarks of cancer. Solute carrier family 2 member 1 (SLC2A1) was a crucial carrier for glucose to enter target cells in the Warburg effect. Yes-associated transcriptional regulator 1 (YAP1), an effector molecule of the hippo pathway, played a crucial role in promoting the development of HCC. This study sought to determine the role of DHA in the SLC2A1 mediated Warburg effect in HCC. In this study, DHA inhibited the Warburg effect and SLC2A1 in HepG2215 cells and mice with liver tumors in situ. Meanwhile, DHA inhibited YAP1 expression by inhibiting YAP1 promoter binding protein GA binding protein transcription factor subunit beta 1 (GABPB1) and cAMP responsive element binding protein 1 (CREB1). Further, YAP1 knockdown/knockout reduced the Warburg effect and SLC2A1 expression by shYAP1-HepG2215 cells and Yap1LKO mice with liver tumors. Taken together, our data indicated that YAP1 knockdown/knockout reduced the SLC2A1 mediated Warburg effect by shYAP1-HepG2215 cells and Yap1LKO mice with liver tumors induced by DEN/TCPOBOP. DHA, as a potential YAP1 inhibitor, suppressed the SLC2A1 mediated Warburg effect in HCC.
- 6 September 2022
- Published by Springer Nature in Journal of Natural Medicines
- Vol. 77 (1) , 28-40
Dihydroartemisinin inhibited the Warburg effect through YAP1/SLC2A1 pathway in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) was the third most common cause of cancer death. But it has only limited therapeutic options, aggressive nature, and very low overall survival. Dihydroartemisinin (DHA), an anti-malarial drug approved by the Food and Drug Administration (FDA), inhibited cell growth in HCC. The Warburg effect was one of the ten new hallmarks of cancer. Solute carrier family 2 member 1 (SLC2A1) was a crucial carrier for glucose to enter target cells in the Warburg effect. Yes-associated transcriptional regulator 1 (YAP1), an effector molecule of the hippo pathway, played a crucial role in promoting the development of HCC. This study sought to determine the role of DHA in the SLC2A1 mediated Warburg effect in HCC. In this study, DHA inhibited the Warburg effect and SLC2A1 in HepG2215 cells and mice with liver tumors in situ. Meanwhile, DHA inhibited YAP1 expression by inhibiting YAP1 promoter binding protein GA binding protein transcription factor subunit beta 1 (GABPB1) and cAMP responsive element binding protein 1 (CREB1). Further, YAP1 knockdown/knockout reduced the Warburg effect and SLC2A1 expression by shYAP1-HepG2215 cells and Yap1LKO mice with liver tumors. Taken together, our data indicated that YAP1 knockdown/knockout reduced the SLC2A1 mediated Warburg effect by shYAP1-HepG2215 cells and Yap1LKO mice with liver tumors induced by DEN/TCPOBOP. DHA, as a potential YAP1 inhibitor, suppressed the SLC2A1 mediated Warburg effect in HCC.
- Open Access
- 10 June 2022
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2022, 1-19
The Effects of Qinghao-Kushen and Its Active Compounds on the Biological Characteristics of Liver Cancer Cells
Background and Aims. Artemisia annua (Qinghao) and Sophora flavescens (Kushen) are traditional Chinese medicines (TCMs). They are widely used in disease therapy, including hepatocellular carcinoma (HCC). However, their key compounds and targets for HCC treatment are unclear. This article mainly analyzed the vital active compounds and the mechanism of Qinghao-Kushen acting on HCC. Methods. First, we chose a traditional Chinese medicine, which has an excellent clinical effect on HCC by network meta-analysis. Then, we composed the Qinghao-Kushen herb pair and prepared the medicated serum. The active compounds of Qinghao-Kushen were verified by the LC-MS method. Next, we detected key targets from PubChem, SymMap, SwissTargetPrediction, DisGeNET, and GeneCards databases. Subsequently, the mechanism of Qinghao-Kushen was predicted by network pharmacology strategy and primarily examined in HuH-7 cells, HepG2 cells, and HepG2215 cells. Results. The effect of the Qinghao-Kushen combination was significantly better than that of single Qinghao or single Kushen in HepG2 and HuH-7 cells. Qinghao-Kushen increased the expression of activated caspase-3 protein than Qinghao or Kushen alone in HepG2 and HepG2215 cells. Network analyses and the LC-MS method revealed that the pivotal compounds of Qinghao-Kushen were matrine and scopoletin. GSK-3β was one of the critical molecules related to Qinghao-Kushen. We confirmed that Qinghao-Kushen and matrine-scopoletin decreased the expression of GSK-3β in HepG2 cells while increased GSK-3β expression in HepG2215 cells. Conclusions. This work not only illustrated that the practical components of Qinghao-Kushen on HCC were matrine and scopoletin but shed light on the inhibitory of Qinghao-Kushen and matrine-scopoletin on liver cancer cells. Moreover, Qinghao-Kushen and matrine-scopoletin had a synergistic effect over the drug alone in HuH-7, HepG2, or HepG2215 cells. GSK-3β may be a potential target for HCC therapy.
- 10 June 2022
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2022, 1-19
Open AccessThe Effects of Qinghao-Kushen and Its Active Compounds on the Biological Characteristics of Liver Cancer Cells
Background and Aims. Artemisia annua (Qinghao) and Sophora flavescens (Kushen) are traditional Chinese medicines (TCMs). They are widely used in disease therapy, including hepatocellular carcinoma (HCC). However, their key compounds and targets for HCC treatment are unclear. This article mainly analyzed the vital active compounds and the mechanism of Qinghao-Kushen acting on HCC. Methods. First, we chose a traditional Chinese medicine, which has an excellent clinical effect on HCC by network meta-analysis. Then, we composed the Qinghao-Kushen herb pair and prepared the medicated serum. The active compounds of Qinghao-Kushen were verified by the LC-MS method. Next, we detected key targets from PubChem, SymMap, SwissTargetPrediction, DisGeNET, and GeneCards databases. Subsequently, the mechanism of Qinghao-Kushen was predicted by network pharmacology strategy and primarily examined in HuH-7 cells, HepG2 cells, and HepG2215 cells. Results. The effect of the Qinghao-Kushen combination was significantly better than that of single Qinghao or single Kushen in HepG2 and HuH-7 cells. Qinghao-Kushen increased the expression of activated caspase-3 protein than Qinghao or Kushen alone in HepG2 and HepG2215 cells. Network analyses and the LC-MS method revealed that the pivotal compounds of Qinghao-Kushen were matrine and scopoletin. GSK-3β was one of the critical molecules related to Qinghao-Kushen. We confirmed that Qinghao-Kushen and matrine-scopoletin decreased the expression of GSK-3β in HepG2 cells while increased GSK-3β expression in HepG2215 cells. Conclusions. This work not only illustrated that the practical components of Qinghao-Kushen on HCC were matrine and scopoletin but shed light on the inhibitory of Qinghao-Kushen and matrine-scopoletin on liver cancer cells. Moreover, Qinghao-Kushen and matrine-scopoletin had a synergistic effect over the drug alone in HuH-7, HepG2, or HepG2215 cells. GSK-3β may be a potential target for HCC therapy.
- Open Access
- 1 September 2014
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 127 (18) , 3204-3208
Associations among cerebral microbleeds, cerebral large-artery diseases and endothelial function
Endothelial dysfunction is not only an early stage of atherosclerosis, but also involved in the pathogenesis of cerebral small-vessel diseases. Patients with cerebral microbleeds (CMBs) may have arteriolosclerosis as well as systemic atherosclerosis. However, little is known about the associations among CMBs, atherosclerosis of cerebral large arteries, and endothelial function. Our study aimed to investigate the relationships among them. This was a cross-sectional study. Ninety patients hospitalized in Peking University First Hospital with acute ischemic stroke were enrolled consecutively between November 1, 2007 and January 31, 2008. All subjects underwent transcranial Doppler and carotid color duplex ultrasonography to record the intima-media thickness (IMT) of common carotid artery, carotid plaque, and cerebral artery stenosis. Brain magnetic resonance imaging (MRI) routine sequences and gradient recall-echo T2*-weighted imaging were performed to count CMBs with clinical data blindness. Endothelial function was evaluated using flow-mediated dilation (FMD) and nitroglycerin-mediated dilation (NMD) of the brachial artery. FMD and NMD were examined by an experienced vascular sonographer using a high-resolution ultrasound. Thirty cases (33.3%) had CMBs with counts ranging from 1 to 30. Both FMD ((9.9±4.8)% vs. (15.2±7.4)%, P=0.001) and NMD ((13.7±6.1)% vs. (19.0±7.4)%, P=0.001) were significantly decreased in CMB-positive patients than in CMB-negative patients. No significant relationships were demonstrated between CMBs and intracranial and/or extracranial artery stenosis. The frequencies of CMBs in patients with IMT <1.0 mm, carotid plaque, and extracranial artery stenosis were 37.5%, 39.4%, and 47.6% respectively, with no significant difference, but much higher than in patients with IMT <1.0 mm (5%, P <0.05). In Logistic regression analysis, impaired FMD (OR=5.783, 95% CI 1.652-6.718, P=0.007) and high pulse pressure (OR=6.228, 95% CI 1.594-3.891, P=0.009) were independently associated with the presence of CMBs, as well as previous ischemic stroke. In contrast, NMD was not correlated with CMBs. CMBs may coexist with cerebral atherosclerosis in ischemic stroke. Endothelial dysfunction may play a role in the pathogenesis of CMBs, but may not simply reflect functional alterations of large arteries.
- 1 September 2014
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 127 (18) , 3204-3208
Open AccessAssociations among cerebral microbleeds, cerebral large-artery diseases and endothelial function
Endothelial dysfunction is not only an early stage of atherosclerosis, but also involved in the pathogenesis of cerebral small-vessel diseases. Patients with cerebral microbleeds (CMBs) may have arteriolosclerosis as well as systemic atherosclerosis. However, little is known about the associations among CMBs, atherosclerosis of cerebral large arteries, and endothelial function. Our study aimed to investigate the relationships among them. This was a cross-sectional study. Ninety patients hospitalized in Peking University First Hospital with acute ischemic stroke were enrolled consecutively between November 1, 2007 and January 31, 2008. All subjects underwent transcranial Doppler and carotid color duplex ultrasonography to record the intima-media thickness (IMT) of common carotid artery, carotid plaque, and cerebral artery stenosis. Brain magnetic resonance imaging (MRI) routine sequences and gradient recall-echo T2*-weighted imaging were performed to count CMBs with clinical data blindness. Endothelial function was evaluated using flow-mediated dilation (FMD) and nitroglycerin-mediated dilation (NMD) of the brachial artery. FMD and NMD were examined by an experienced vascular sonographer using a high-resolution ultrasound. Thirty cases (33.3%) had CMBs with counts ranging from 1 to 30. Both FMD ((9.9±4.8)% vs. (15.2±7.4)%, P=0.001) and NMD ((13.7±6.1)% vs. (19.0±7.4)%, P=0.001) were significantly decreased in CMB-positive patients than in CMB-negative patients. No significant relationships were demonstrated between CMBs and intracranial and/or extracranial artery stenosis. The frequencies of CMBs in patients with IMT <1.0 mm, carotid plaque, and extracranial artery stenosis were 37.5%, 39.4%, and 47.6% respectively, with no significant difference, but much higher than in patients with IMT <1.0 mm (5%, P <0.05). In Logistic regression analysis, impaired FMD (OR=5.783, 95% CI 1.652-6.718, P=0.007) and high pulse pressure (OR=6.228, 95% CI 1.594-3.891, P=0.009) were independently associated with the presence of CMBs, as well as previous ischemic stroke. In contrast, NMD was not correlated with CMBs. CMBs may coexist with cerebral atherosclerosis in ischemic stroke. Endothelial dysfunction may play a role in the pathogenesis of CMBs, but may not simply reflect functional alterations of large arteries.
- Open Access
- 28 November 2013
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 42 (1) , 67-76
Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients
Objective: To investigate the prevalence and implication of cytochrome P450, family 2, subfamily C, polypeptide 9 ( CYP2C9 ) variants and vitamin K epoxide reductase complex, subunit 1 ( VKORC1 )-1639 G > A polymorphisms in Chinese patients receiving warfarin therapy. Methods: Chinese Han patients requiring oral warfarin therapy were consecutively enrolled. Correlations between CYP2C9 *1, *2, *3, *4, *5 variants and VKORC1 -1639 G > A polymorphisms, fourth-day international normalized ratios (INRs) and warfarin maintenance dose were investigated. Results: Out of 101 patients, there were no significant differences in fourth-day INR or warfarin daily maintenance doses between patients with CYP2C9 *1*1 and CYP2C9 *1*3 genotypes. Patients with the VKORC1 -1639 AA genotype had a higher fourth-day INR (1.87 ± 0.14) than those with the VKORC1 -1639 AG genotype (1.32 ± 0.15). Warfarin maintenance dose for patients with the VKORC1 -1639 AA genotype (2.40 ± 0.70 mg/day) was significantly lower than for patients with the VKORC1 -1639 AG genotype (4.83 ± 0.70 mg/day). Conclusions: Unlike Caucasian populations, VKORC1 -1639 G > A polymorphisms in the Chinese population may be the dominant genetic factors associated with warfarin response variability.
- 28 November 2013
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 42 (1) , 67-76
Open AccessVariability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients
Objective: To investigate the prevalence and implication of cytochrome P450, family 2, subfamily C, polypeptide 9 ( CYP2C9 ) variants and vitamin K epoxide reductase complex, subunit 1 ( VKORC1 )-1639 G > A polymorphisms in Chinese patients receiving warfarin therapy. Methods: Chinese Han patients requiring oral warfarin therapy were consecutively enrolled. Correlations between CYP2C9 *1, *2, *3, *4, *5 variants and VKORC1 -1639 G > A polymorphisms, fourth-day international normalized ratios (INRs) and warfarin maintenance dose were investigated. Results: Out of 101 patients, there were no significant differences in fourth-day INR or warfarin daily maintenance doses between patients with CYP2C9 *1*1 and CYP2C9 *1*3 genotypes. Patients with the VKORC1 -1639 AA genotype had a higher fourth-day INR (1.87 ± 0.14) than those with the VKORC1 -1639 AG genotype (1.32 ± 0.15). Warfarin maintenance dose for patients with the VKORC1 -1639 AA genotype (2.40 ± 0.70 mg/day) was significantly lower than for patients with the VKORC1 -1639 AG genotype (4.83 ± 0.70 mg/day). Conclusions: Unlike Caucasian populations, VKORC1 -1639 G > A polymorphisms in the Chinese population may be the dominant genetic factors associated with warfarin response variability.